Full Time Faculty

He manages research teams with infectious disease laboratories in each of these facilities. His medical boards are in Preventive Medicine and Public Health. Dr. Gray has conducted diverse epidemiological studies of infectious diseases for 25 years in 5 continents. Much of his work has involved identifying risk factors for occupational diseases, particularly for infectious diseases. He has a special research interest in studying respiratory viruses and zoonotic pathogens. He has studied numerous occupational groups including farmers, animal breeders, veterinarians, military personnel, turkey workers, poultry workers, horse workers, hunters, and pig workers. A strong supporter for the One Health approach, he has won multiple One Health research and training grants, established two centers of One Health (USA & Romania) and developed 4 graduate programs in One Health (PhD, MHS, and Certificate). He has authored more than 270 peer-reviewed manuscripts and book chapters. Currently, he serves on the Editorial Board for the journal Influenza and Other Respiratory Viruses. His work in China have resulted in more than 30 research publications, funding as a high-end expert, and a visiting professorship. In 2014, he helped to organize the first One Health International Symposium in China (Guangzhou). He currently serves as principal investigator for a five-year NIH R01 grant studying swine influenza virus transmission in China.

” (Health Affairs, March/April 2006) which led to the Sec. 524 amendment in the Food and Drug Administration Amendments Act of 2007.  The article recommended, and the legislation made into law, a new incentive for neglected tropical disease medicines: the priority review voucher (PRV).  A PRV is awarded for US registration of a new medicine (new chemical, biological) for a voucher-eligible disease (19 high burden and emergent diseases including TB, malaria and Ebola).  An awarded voucher is exercised on a second drug that receives priority review as a reward for registration of the disease-eligible drug.  FDA awarded the first voucher to Coartem® in 2009 and 13 vouchers have been awarded as of February 2017.  The PRV program was amended in 2012 and again in 2016 to make pediatric cancer medicines and rare pediatric diseases voucher eligible.  4 vouchers have been awarded for neglected tropical diseases and 9 for other pediatric voucher-eligible diseases.  In August 2017, Moe co-authored an article advocating for the creation of a new incentive for vector control agents (“A Voucher System To Speed Review Could Promote A New Generation Of Insecticides To Fight Vector-Borne Diseases” (Ridley, Moe & Hamon, Health Affairs, August 7, 2017)

In response to requests by the Development Research Center of the Chinese State Council, Moe has led international country comparator studies regarding drug procurement and the use of specialists in health care.  Those research papers have been translated into Chinese and published by the China Development Press.  His research interests include incentives to stimulate research and development of new medicines for global diseases; identification and replication of health care delivery innovation, global health ethics and “reverse innovation” where new products and services introduced in Southern low resource settings have application in the higher income West.

Moe received his Ph.D. in Organization Development and Behavior from the University of North Carolina at Chapel Hill, 1981.  He graduated from the Kellogg School, Northwestern University, Executive Development Program in 1997.  Moe has previously been a lecturer at the University of Witwatersrand in Johannesburg, South Africa.

He is also Associate Director of DGHI for China Initiatives, and Executive Director of Global Health Program at Duke Kunshan University in China, as well as Director of Research Hub for Asia-Pacific Observatory on Health Systems and Policies/WHO, which has research projects in Cambodia, Nepal, Vietnam and other Asian countries. In his capacity at Duke Kunshan University, he was elected as President of Chinese Consortium of Universities for Global Health (CCUGH) in November 2015. Tang has more than 30 years of experience undertaking research on health systems reform, disease control and maternal and child health in China and other countries, and has provided consultancy services on health systems strengthening to many international organizations and governments of developing countries. In 2012, Tang came to Duke from the UNICEF/UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR), based in Geneva, where he was Unit Leader for TB/HIV and Health Systems. Before his assignment at WHO, Tang was a faculty member at Liverpool School of Tropical Medicine in UK, and School of Public Health of Fudan University (former Shanghai Medical University).

He directs the Exposure Biology and Chemistry Laboratory. He also directs the Regional Ozone Sino-US Collaborative Research Center. Professor Zhang’s main research interests include exposure science and environmental health sciences. Dr. Zhang authored more than 180 peer-reviewed articles, including those published in top biomedical journals (NJEM, the Lancet, JAMA) and environmental sciences journals. His early work on characterizing sources of non-methane greenhouse gases made him one of the officially recognized contributors to the 2007 Nobel Peace Prize awarded to IPCC. He is the 2012 recipient of the Jerome Wesolowski Award, the highest honor of the International Society of Exposure Science.  In 2013, Professor Zhang was named an AAAS Fellow.